Heparin ointment (Heparin ointment)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceHeparin sodium + Benzocaine + Benzyl nicotinateHeparin sodium + Benzocaine + Benzyl nicotinate
Similar drugsTo uncover
  • Heparin
    ointment externally 
    BIOSINTEZ, PAO     Russia
  • Heparin ointment
    ointment externally 
    BELMEDPREPARATY, RUP     Republic of Belarus
  • Heparin ointment
    ointment externally 
    NIZHFARM, JSC     Russia
    • Dosage form: & nbspointment for external use
    Composition:

    1 g of ointment contains:

    active ingredients: heparin sodium - 100 ME (0.833 mg with heparin sodium activity 120 IU / mg), benzocaine - 40.0 mg, benzyl nicotinate - 0.8 mg;

    Excipients:

    Glycerol 150 mg, petrolatum 60 mg, stearic acid 50 mg 50 mg, peach oil 50 mg, emulsifier No. 1 50 mg methyl parahydroxy benzoate 1.5 mg propyl parahydroxybenzoate 0.5 mg water, up to 1 g.

    Description:Ointment from white to white with a yellowish hue of color.
    Pharmacotherapeutic group:Anticoagulant direct action for topical application + other drugs
    ATX: & nbsp

    C.05.B.A   Heparin-containing preparations for topical application

    C.05.B.A.53   Heparin in combination with other drugs

    Pharmacodynamics:

    Combination drug for external use, the effect of which is due to the properties of its constituent components. Heparin - an anticoagulant of direct action, belongs to the group of medium-molecular heparins.With external application has a local anticoagulant, anti-exacerbation, moderate anti-inflammatory effect. It blocks the formation of thrombin. Heparin reduces the inflammatory process and has an anticoagulant effect, indirectly improves microcirculation, which contributes to the process of resorption of hematomas and blood clots and a reduction in swelling of the tissues.

    Benzylnicotinate is a peripheral vasodilator, improves microcirculation. Used as an adjuvant to improve the penetration of heparin.

    Benzocaine has a local anesthetic effect. Reduces the permeability of the cell membrane for sodium ions, displaces calcium ions from receptors located on the inner surface of the membrane, blocks the conduct of nerve impulses. Prevents the appearance of painful impulses in the endings of the sensory nerves and their conduction along nerve fibers.

    Pharmacokinetics:

    Heparin is slightly absorbed from the surface of the skin. The connection with plasma proteins is up to 95%, the volume of distribution is 0.06 l / kg. It does not penetrate the placenta and into breast milk.Intensively captured by endothelial cells and cells of the mononuclear-macrophage system, concentrated in the liver and spleen. It is metabolized in the liver with the participation of N-desulfamidase and platelet heparinase, which is included in the metabolism of heparin at later stages. Desulfated molecules under the influence of kidney endoglycosidase are converted into low-molecular fragments. Half-life (T1/2) - 1-6 hours (on average - 1.5 hours); increases with obesity, hepatic and / or renal insufficiency; decreases with thromboembolism of the pulmonary artery, infections, malignant tumors. It is excreted by the kidneys, mainly in the form of inactive metabolites. It is not excreted by hemodialysis.

    Benzylnicotinate penetrates all layers of the skin. In the systemic blood flow is almost not received.

    Benzocaine for external use is practically not absorbed.

    Indications:Thrombophlebitis of superficial veins, superficial periphlebitis; subcutaneous hematoma; postinjection and postinfusion phlebitis; superficial mastitis; localized infiltrates and edema, injuries and bruises (including muscle tissue, tendons, joints); external hemorrhoids, inflammation of postpartum hemorrhoids; lymphedema (elephantiasis), lymphangitis.
    Contraindications:Hypersensitivity to the components of the drug; violation of the integrity of the skin of the affected area (open infected wounds, ulcerative necrotic processes in particular); children under 1 year.
    Carefully:Violations of the blood coagulation system, thrombocytopenia.
    Pregnancy and lactation:The safety of the drug during pregnancy and lactation is not established. Heparin does not pass through the placental barrier and is not excreted in breast milk. Information about the ingestion of other components of the drug in breast milk is not. Heparin ointment is used during pregnancy and lactation (breastfeeding) only if the intended benefit for the mother exceeds the potential risk to the fetus or child.
    Dosing and Administration:

    Outwardly. The ointment is applied a thin layer on the affected area (at the rate of 0.5-1 g (2-4 cm of ointment) per section 3-5 cm in diameter) and gently rubbed into the skin. Ointment is applied 2-3 times a day daily until the disappearance of inflammatory phenomena, on average 3 to 7 days. The possibility of a longer treatment is determined by the doctor.

    In thrombosis of external hemorrhoids, rectal tampons are used,the ointment is applied to a coarse or linen pad, which is applied directly to the thrombosed units and fixed. An ointment soaked in ointment is injected into the anus. Ointment should be applied daily, until the symptoms disappear, on average 3-14 days.

    Side effects:With prolonged use of the drug, local reactions in the form of skin hyperemia, a decrease in sensitivity at the site of application, allergic reactions (skin rash, itching) are possible.
    Overdose:Due to low systemic absorption, an overdose is unlikely.
    Interaction:Ointment is not prescribed topically at the same time as non-steroidal anti-inflammatory drugs (NSAIDs), tetracyclines, H1-histamine receptor blockers.
    Special instructions:

    With prolonged use of Heparin ointment on large areas and simultaneous administration of oral medications that affect the blood coagulation system and / or hematopoiesis, coagulation time and prothrombin time should be monitored.

    If a prolonged course of treatment is required and in large areas of the lesion in pregnant women and women over the age of 65, similar control is recommended.

    Do not apply to open wounds, in the presence of purulent processes.

    The use of ointment is not recommended for deep venous thrombosis.

    Effect on the ability to drive transp. cf. and fur:The drug does not adversely affect the ability to drive vehicles and work with mechanisms.
    Form release / dosage:Ointment for external use.
    Packaging:

    By 25 grams in tubes of aluminum or in tubes of polyethylene laminate.

    Each tube together with instructions for medical use of the drug is placed in a pack of cardboard.

    Storage conditions:At a temperature not exceeding 20 ° C. Keep out of the reach of children.
    Shelf life:

    3 years.

    Do not use the product after the expiry date printed on the package.

    Terms of leave from pharmacies:Without recipe
    Registration number:P N000314 / 01
    Date of registration:19.08.2011 / 29.05.2013
    Expiration Date:Unlimited
    The owner of the registration certificate:NIZHFARM, JSC NIZHFARM, JSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp27.03.2017
    Illustrated instructions
      Instructions
      Up